Weight Management

The American Diabetes Association guidelines have self-care and lifestyle recommendations for patients and health care professionals.

Lifestyle modifications are the cornerstone of treatment.

These clear-cut guidelines help pharmacists making sure the patients are getting the right drug to set them up for success and prevent problems down the road.

The future trend in managing diabetes will extend into glycemic control, weight reduction, and renal liver, for example.

In February of this year, the new statistics came out where we're at now 37 million with diabetes and 96 million with prediabetes.

Semaglutide (Wegovy) is indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in adult patients.

Insurers are refusing to cover new, highly effective anti-obesity drugs, but some prescribers are getting around the issue.

Contrave is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults.

Physicians often overlook those with lower BMIs who have nonalcoholic fatty liver disease and lower rates of other comorbidities, investigators say.

Clinical trial participants who took the drug lost up to 52 lb., or 24 kg, in the 72-week, phase 3 study.

Ertugliflozin (Steglatro) is a sodium glucose co-transporter 2 inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Psychedelic medicines like psilocybin work to re-wire the brain, potentially addressing the root cause of eating disorders rather than the symptoms.

In a clinical trial, 86.4% of patients on semaglutide achieved a 5% weight loss at week 68 compared to 31.5% with placebo.

Estosterone undecanoate (Tlando; Antares Pharma, Inc) is indicated as testosterone replacement therapy for conditions associated with a deficiency or absence of endogenous testosterone in adult patients.

Semaglutide (Ozempic; Novo Nordisk) approved as a once-weekly subcutaneous injection for the treatment of adults with type 2 diabetes.

Basaglar is indicated to improve glycemic control in adults and children with type 1 diabetes and adults with type 2 diabetes.

Empagliflozin and linagliptin (Glyxambi) is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Results of studies show that women with obesity who get these weight loss procedures often also have preventative benefits.

Ozempic is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Increasing physical activities and reducing caloric intake isn’t always enough to conquer obesity.

New study results show that rapidly adding pounds in the first and final months of gestation likely plays a key role in the development of excess fat tissue in female children and adolescents.

Even after taking cardiovascular risks or vascular brain injury into account, the association remained, study results show.

Limited empirical data from new study suggests correlations between obesity and individual SDOH, such as education level, food environment, income, and neighborhood.

Investigators found that an additional hour of sleep correlated with a 26% decrease in an infant’s risk of being overweight.

Pharmacists can help to reduce the prevalence of food insecurity and its negative health care outcomes by tailoring clinical care to each individual patient’s needs.